# A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma

> **NCT04533321** · PHASE2 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 20 (estimated)

## Conditions studied

- Squamous Cell Carcinoma

## Interventions

- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT04533321
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09
- **Primary completion:** 2023-09
- **Final completion:** 2023-09
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04533321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04533321, "A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT04533321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*